Gilead Sciences (GILD) PT Raised to $83 at RBC Capital, 'HIV IP Settlement Should Add $22B Aggregate Revs'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $83.00 (from $79.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
